Anzeige
Mehr »
Login
Dienstag, 17.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Revolution im Wasserstoffmarkt: Diese Aktie könnte der nächste Überflieger sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
1.044 Leser
Artikel bewerten:
(2)

Diagnostic Medical Systems: Fujifilm Healthcare Italy wins tender for 96 X-ray tables

Finanznachrichten News

DMS Imaging, the imaging division of Diagnostic Medical Systems Group (Euronext Growth Paris - FR0012202497 - ALDMS) and French specialist in the development, design, and manufacture of imaging systems is pleased to announce that its commercial and industrial partner Fujifilm Healthcare Italy has won a tender for 96 FDX Visionary-RF Premium remote-controlled radiology tables.

This order is part of the national tender launched by CONSIP, a public company owned by the Italian Ministry of Economy and Finance.

This volume of remote-controlled tables, the majority of which will be delivered in 2023, represents, in terms of turnover, the largest tender ever awarded to DMS Imaging.

Europe was the initial starting point for the commercial and industrial agreements signed between Fujifilm Healthcare and DMS Imaging at the RSNA (Radiological Society of North America) at the end of 2019.

In the first nine months of 2022, the sales of FDX Visionary-RF Premium tables represented about 30% of the reported market share in France (source: SNITEM - Syndicat National de l'Industrie des Technologies Médicales).

This new contract allows DMS Imaging and Fujifilm Healthcare to establish themselves as major players in Italy as well. The activities in the rest of Europe are also growing steadily.

Since 2020, the DMS Imaging and Fujifilm Healthcare Europe agreements have been extended to the United States and EMEA area, which represent major growth vectors. Discussions are underway to extend the collaboration to Central and South America.

Masa Fukumoto, President of Fujifilm Healthcare Europe, declares:
" We are very pleased with our partnership with DMS Imaging and our recent achievements in Europe show how relevant this collaboration is. Fujifilm Group aims to become a key player on the medical imaging market and DMS Imaging's Group 's products fit perfectly with our portfolio. The achievement on the CONSIP call for bids and all other recent achievements in Europe proves it perfectly. "

Samuel Sancerni, Chairman & CEO of DMS Group, comments:
" Historically, France and Italy are the two largest European markets for remote-controlled tables. Our partnership with Fujifilm Healthcare has established us as one of the major actors in the French market. This contract will allow us to grow our market share in the Italian market over the long term. This order represents about 30% of annual turnover for our medical imaging activity. Our new production and assembly unit and the refocusing of our corporate strategy on our imaging business over the last few months allows us to accompany our partners in their market growth. I would like to thank our partner Fujifilm Healthcare Italy for their trust in this contract. "

About DMS Group
The DMS Group is a French specialist and recognized player in medical imaging, with high-end imaging solutions dedicated to digital radiology and bone densitometry, through its DMS Imaging division.
Specialized in high technology for medical diagnosis, DMS Group is now the French leader in development, design and manufacturing of RF imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.
The DMS Group is on every continent through a network of over 140 national distributors, subsidiaries and joint ventures.
DMS Biotech division, consisting of Hybrigenics listed on the Paris Euronext Growth market (ISIN: FR0004153930 - ticker: ALHYG) and its subsidiaries, operates in the field of biotechnologies, and more specifically, technologies for the treatment of osteoarthritis and regenerative medicine based on the injection of fat stem cells. DMS Group concluded a memorandum of understanding to organize the sale of its DMS Biotech.
DMS Group is quoted on the Paris Euronext market (ISIN: FR0012202497 - memo: ALDMS).

More information on www.dms.com.

FREE SUBSCRIPTION TO THE FINANCIAL INFORMATION OF DMS GROUP AT WWW.ACTUSNEWS.COM.

Contacts

DMS Group
Samuel SANCERNIChairman & CEO+33(0)4 67 50 49 00
ACTUS FINANCE
Mathieu OMNESInvestors relations+33(0)1 53 67 36 92
Serena BONIPress Relations+33(0)4 72 18 04 92
------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: xWmdlsVukpjIx2xwl55nl2Fkl29qmWbKlmOcx2hxmJqcbJuTxWdpaJTIZnBplWZq
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-78014-dms_pr_fujifilm-italie_12012023_en.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2023 Actusnews Wire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.